Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis

Children diagnosed and treated for miscellaneous bowel diseases

Hirschsprung's Disease Associated Enterocolitis

Kinderchirurgie Universität Heidelberg

Ospedale Regionale di Bellinzona e Valli

Inselspital Universität Bern

Hôpitaux Universitaires Genève

Bâtiment Hospitalier CHUV

Luzerner Kantonsspital

Kinderspital St. Gallen

Kinderspital Zürich

Neuro-Immune Interactions in the Gut

The Enteric Nervous System as Modulator of Mucosal Immune Cells

Determining cell frequencies and subtypes using fluorescence-activated cell sorting (FACS) and FlowJo software

RNA expression profile of whole colon tissue and single cell populations

Microscopic analysis of colonic tissue using immunofluorescence and immunohistochemistry

Targeted Sanger sequencing of known Hirschsprung's disease associated genes

Simone Keck

Dr. Simone Keck

University Children's Hospital Basel

University Children's Hospital, Zurich

Universität Klinikum Heidelberg

This group will be prescribed a dose of antibiotics (Septra 2mg/kg)

Receive probiotic plus an antibiotic placebo

This group will be on a dose of probiotics (2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule) plus a antibiotic (Septra)

Urinary Tract Infection

Antibiotic

2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule

Probiotic

London Health Sciences Centre

Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder

A Clinical Trial to Determine the Extent to Which Probiotic Therapy Reduces Side Effects of Antibiotic Prophylaxis in Pediatric Neurogenic Bladder Patients With a History of Recurrent Urinary Tract Infections

Use a questionnaire to assess frequency and type of side effect while on prophylactic antibiotic, antibiotic plus probiotic or probiotic plus placebo

Mean number of RUTI episodes (>105 colony forming unit (CFU)/mL from a catheter specimen, with leukocyturia (>10/HPF) and the presence of symptoms and signs such as fever (>38.5°C), flank pain or suprapubic pain) during a 6 month follow-up period.

the time it takes for a study subject to develop a urinary tract infection

Changes in pro-inflammatory cytokines (IL-6, TNF (tumor necrosis factor)-α) and pro-inflammatory chemokine (IL-8) associated with inflammation and immune cell recruitment. Urinary levels of each factor will be measured using multiplexed immunoassay kits employing Luminex® xMAP fluorescent bead-based technology (Luminex Corporation, Austin, TX) and the Bio-Plex 200 readout system (Bio- Rad Laboratories Inc., Hercules, California.

Changes in metabolomic profiles of urine, as measured by Gas chromatography mass spectrometry (GS-MS) and nuclear magnetic resonance (NMR)

Bladder storage function (capacity, compliance, overactivity).

Dr. Sumit Dave

Assistant Professor, Pediatric Urologist

Canadian Urological Association

Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months

VSL#3 probiotic
VSL#3 : Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.
E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.

VSL#3 Probiotic

Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
Placebo : Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months

Placebo

Total

Sex: Female, Male

Region of Enrollment

The primary outcome measure is reporting the number of participants diagnosed with Hirschsprung-associated enterocolitis (HAEC) after pullthrough procedure.

VSL#3: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.
E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.

Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
Placebo: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months

Number of Patients Diagnosed With Hirschsprung-associated Enterocolitis (HAEC).

The severity of clinical episodes of HAEC will be stratified into three grades (mild, moderate, or severe). Grades of severity reported are based on first episodes.

VSL#3 : Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.
E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.

Severity of Clinical Episodes of HAEC

Overall Study

Daniel Teitelabum

Hirschsprung Disease

Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.
E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.

mucin/ethet

Neuro-Immune Interactions in the Gut

Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder

Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)

Baza e të dhënave më e plotë e bimëve medicinale e mbështetur nga shkenca